NeuroOne (NMTC) Market Dev Director Mark Christianson Receives Award

What Happened
Mark Christianson, Market Development Director at NeuroOne Medical Technologies Corp (NMTC), was granted 12,500 shares as an award on 2026-08-28. The award is recorded as a derivative acquisition with a reported price of $0.00 (i.e., a grant/compensation award, not an open-market purchase or sale).

Key Details

• Transaction date: 2026-08-28; transaction type: Award/Grant (code A).
• Shares granted: 12,500; reported price: $0.00 (derivative award).
• Vesting (footnote): 25% vests on Aug 28, 2027; remaining 75% vests in 12 equal quarterly installments (9,375 shares total; ~781.25 shares per quarter).
• Shares owned after transaction: Not specified on the Form 4 filing.
• Filing timeliness: No late filing indicated.

Context
This is a compensation award subject to time-based vesting, a common way companies retain employees. Because the award vests over time, it does not represent immediate market activity (no immediate sale or cash exercise). Such grants are routine executive/employee compensation and should not be interpreted alone as a definitive signal of insider sentiment.